BioMarin Pharmaceuticals
BMRNBioMarin Pharmaceutical Inc. is a global biotechnology company specializing in the discovery, development, and commercialization of first-in-class therapies for rare genetic diseases.
Earnings
Next report
Oct 26, 2026 (in a month)Valuation & ratios
Segments
Competitors
By market cap
By revenue growth
By net margin
Profile
BioMarin Pharmaceutical Inc. is a global biotechnology company specializing in the discovery, development, and commercialization of first-in-class therapies for rare genetic diseases. The company leverages genetic science to address the root causes of life-threatening conditions, maintaining a robust portfolio of commercial enzyme replacement therapies and a deep clinical pipeline targeting skeletal and metabolic disorders.
A leading global player in the rare disease space with a dominant position in enzyme replacement therapies and a first-mover advantage in achondroplasia treatments.
FAQ
- What is BioMarin Pharmaceuticals's market cap?
- BioMarin Pharmaceuticals (BMRN) has a market capitalization of $12.5B and trades on NASDAQ.
- What is BioMarin Pharmaceuticals's revenue and profitability?
- BioMarin Pharmaceuticals generated $3.4B in trailing twelve-month revenue with net income of $360.1M, representing a net margin of 16.8%. Gross margin stands at 76.1%, with free cash flow of $738.2M. The latest reported period is Q2 2026.
- Who are BioMarin Pharmaceuticals's competitors?
- BioMarin Pharmaceuticals's key competitors include BridgeBio Pharma, Inc., PTC Therapeutics, Inc., Sarepta Therapeutics, Inc., and others. These companies compete in similar markets and product categories.
- Who does BioMarin Pharmaceuticals partner with?
- BioMarin Pharmaceuticals's notable partners include Sanofi.
- What subsidiaries does BioMarin Pharmaceuticals have?
- BioMarin Pharmaceuticals's subsidiaries include Inozyme Pharma, Inc., Amicus Therapeutics, Inc., BioMarin/Genzyme LLC.
- Where is BioMarin Pharmaceuticals headquartered?
- BioMarin Pharmaceuticals is headquartered in United States of America and employs approximately 3,401 people. It has been publicly traded since 1999.
